Phase II trial of vindesine in breast cancer, lymphoma and other tumors: future directions.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014748:Vinca Alkaloids / Q000627:therapeutic use*; D014751:Vindesine
D000970:Antineoplastic Agents; D014748:Vinca Alkaloids; D014747:Vinblastine; D014751:Vindesine